AzTrials
AzTrials

Diabetic Foot UlcerPhase 2/3FEENICSNCT00662831

Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients

A Phase 2/3 study testing Fragmin/ Dalteparin Sodium in people with Diabetic Foot Ulcer, run by Pfizer at 63 sites in 17 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetic Foot Ulcer
What is being tested?
Fragmin/ Dalteparin Sodium
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
276 participants
Where
63 sitesin 17 countries
Study dates
Apr 2008to Oct 2010
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects 18 years of age with type 1 or type 2 diabetes.
  • Subjects with peripheral occlusive arterial disease (PAOD) and a neuropathy disability score (NDS) of >3

Who cannot join

  • Subjects who have undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Subjects with an ulcer grading of 0 or 3 and staging of A, B or D according to the University of Texas wound classification system.
  • Subjects with a known bleeding disorder or evidence of active bleeding.

Trial locations and contacts

63 sites in 17 countries.

63 sites in 17 countries

United Kingdom9 sites
  • Pfizer Investigational Site

    Barnsley, S75 2EP

  • Pfizer Investigational Site

    Birmingham, B9 5SS

  • Pfizer Investigational Site

    Colchester, CO4 5JL

  • Pfizer Investigational Site

    Coventry, CV2 2DX

  • Pfizer Investigational Site

    Dundee, DD1 9SY

  • Pfizer Investigational Site

    Ipswich, IP4 5PD

  • Pfizer Investigational Site

    Manchester, M13 0JE

  • Pfizer Investigational Site

    Manchester, M13 9WL

  • Pfizer Investigational Site

    Peterborough, PE3 9GZ

Other trials in United Kingdom

Sweden7 sites
  • Pfizer Investigational Site

    Karlstad, 651 85

  • Pfizer Investigational Site

    Malmö, 205 02

  • Pfizer Investigational Site

    Stockholm, 11883

  • Pfizer Investigational Site

    Stockholm, 141 86

  • Pfizer Investigational Site

    Stockholm, 17176

  • Pfizer Investigational Site

    Stockholm, 182 88

  • Pfizer Investigational Site

    Stockholm, 18288

Other trials in Sweden

Denmark6 sites
  • Pfizer Investigational Site

    Aalborg, 9100

  • Pfizer Investigational Site

    Aarhus C, 8000

  • Pfizer Investigational Site

    Hvidovre, 2650

  • Pfizer Investigational Site

    Koebenhavn NV, 2400

  • Pfizer Investigational Site

    Odense C, 5000

  • Pfizer Investigational Site

    Sønderborg, 6400

Other trials in Denmark

Russia6 sites
  • Pfizer Investigational Site

    Moscow, 109240

  • Pfizer Investigational Site

    Moscow, 115998

  • Pfizer Investigational Site

    Moscow, 119034

  • Pfizer Investigational Site

    Moscow, 123423

  • Pfizer Investigational Site

    Moscow, 127486

  • Pfizer Investigational Site

    Saint Petersburg, 194156

Other trials in Russia

Poland5 sites
  • Pfizer Investigational Site

    Gdansk, 80-952

  • Pfizer Investigational Site

    Lodz, 90-153

  • Pfizer Investigational Site

    Puławy, 24-100

  • Pfizer Investigational Site

    Warsaw, 02-097

  • Pfizer Investigational Site

    Wroclaw, 51-124

Other trials in Poland

Greece4 sites
  • Pfizer Investigational Site

    Athens, 106 76

  • Pfizer Investigational Site

    Athens, 11527

  • Pfizer Investigational Site

    Melissia/Athens, 15127

  • Pfizer Investigational Site

    Thessaloniki, 56429

Other trials in Greece

Italy4 sites
  • Pfizer Investigational Site

    Florence, 50139

  • Pfizer Investigational Site

    Pisa, 56124

  • Pfizer Investigational Site

    Roma, 00133

  • Pfizer Investigational Site

    San Giovanni Rotondo, FG, 71013

Other trials in Italy

Ukraine4 sites
  • Pfizer Investigational Site

    Kharkiv, 61002

  • Pfizer Investigational Site

    Kyiv, 02091

  • Pfizer Investigational Site

    Lviv, 79010

  • Pfizer Investigational Site

    Odesa, 65009

Other trials in Ukraine

Austria3 sites
  • Pfizer Investigational Site

    Klagenfurt, A-9020

  • Pfizer Investigational Site

    Vienna, A-1030

  • Pfizer Investigational Site

    Vienna, A-1090

Other trials in Austria

Czechia3 sites
  • Pfizer Investigational Site

    Prague, 140 21

  • Pfizer Investigational Site

    Prague, 150 06

  • Pfizer Investigational Site

    Zlín, 760 01

Other trials in Czechia

Lithuania3 sites
  • Pfizer Investigational Site

    Kaunas, 49476

  • Pfizer Investigational Site

    Vilnius, 01102

  • Pfizer Investigational Site

    Vilnius, 10207

Other trials in Lithuania

Spain3 sites
  • Pfizer Investigational Site

    Getafe, Madrid, 28905

  • Pfizer Investigational Site

    Girona, 17007

  • Pfizer Investigational Site

    Madrid, 28040

Other trials in Spain

Canada2 sites
  • Pfizer Investigational Site

    Montreal, Quebec, H1T 2M4

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1R9

Other trials in Canada

Belgium1 site
  • Pfizer Investigational Site

    Ransart, 6043

Other trials in Belgium

Finland1 site
  • Pfizer Investigational Site

    Tampere, 33520

Other trials in Finland

Germany1 site
  • Pfizer Investigational Site

    Karlsbad, 76307

Other trials in Germany

Norway1 site
  • Pfizer Investigational Site

    Tønsberg, 3103

Other trials in Norway

About this study

Official title: A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients

The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.

Being tested
Fragmin/ Dalteparin Sodium, Placebo for Fragmin/ Dalteparin Sodium
Keywords
Diabetic Foot Ulcers Neuroischaemic
Medical subject headings
Diabetic Foot

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fragmin/ Dalteparin SodiumDrug

    Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.

  • Placebo for Fragmin/ Dalteparin SodiumDrug

    Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.

Study groups in NCT00662831
Study groupRoleWhat they receive
ActiveExperimentalActive study treatment
Receives: Drug: Fragmin/ Dalteparin Sodium
PlaceboPlacebo comparatorPlacebo
Receives: Drug: Placebo for Fragmin/ Dalteparin Sodium

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing

    University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.

    Measured: Week 24 [end of treatment (EOT)] or early termination

Secondary outcomes (13)
  1. Number of Participants With Intact Skin Healing

    Intact skin healing was defined as 100 percent reduction in ulcer surface area with full epithelialisation. UT system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.

    Measured: Week 24 (EOT) or early termination

  2. Number of Participants Who Underwent Any Amputation

    Any amputation included both major and minor amputations. A major amputation was defined as above the ankle and was reported as below-the-knee and above-the-knee amputations. A minor amputation was defined as below the ankle amputation.

    Measured: Week 24 (EOT) or early termination

  3. Number of Participants Who Underwent Major and Minor Amputation

    A major amputation was defined as above the ankle and was reported as below-the-knee and above-the-knee amputations. A minor amputation was defined as below the ankle amputation.

    Measured: Week 24 (EOT) or early termination

  4. Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Excluding Intact Skin Healing

    University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure<=30 mmHg and UT grade and stage 2C.

    Measured: Week 24 (EOT) or early termination

  5. Number of Participants Who Died

    Measured: Week 24 (EOT) or early termination

  6. Number of Participants With Major Cardiovascular Disease Events (MCVE)

    Major cardiovascular events were defined as death due to vascular cause; non-fatal myocardial infarction (MI) excluding procedure related to MI; coronary revascularization procedures not related to MIs; hospitalization for unstable angina or non-fatal stroke.

    Measured: Week 24 (EOT) or early termination

  7. Time to Intact Skin Healing

    Median time taken to achieve intact skin healing which was defined as 100 percent reduction in ulcer surface area with full epithelialisation.

    Measured: Week 24 (EOT) or early termination

  8. Median Time to First Amputation

    Measured: Week 24 (EOT) or early termination

  9. Euro Quality of Life-5 Dimensions (EQ-5D)- Utility Score

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline and Week 24 (EOT or early termination)

  10. Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Measured: Baseline and Week 24 (EOT or early termination)

  11. 36-Item Short-Form Health Survey (SF-36) Score

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline and Week 24 (EOT or early termination)

  12. 11-point Likert Pain Scale

    The 11 point Likert pain scale which used a 0 (no pain) to 10 (worst possible pain) point rating system was used to assess participant's pain score. No distinction was made between neuropathy and inflammatory (nociceptive) pain.

    Measured: Baseline and Week 24 (EOT or early termination)

  13. Transcutaneous Local Tissue Oxygenation (pO2)

    Transcutaneous pO2 was assessed at the dorsum of the foot in the first intermetatarsal space using an appropriately calibrated instrument. The skin oxygen partial pressure was determined by measuring the oxygen reduction current by means of a measuring cell.

    Measured: Baseline and Week 24 (EOT or early termination)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Apr 2008 (estimated)
  2. Study startApr 2008
  3. Primary completionOct 2010
  4. Study completionOct 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
276 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00662831
Sponsor's protocol ID
A6301083
Acronym
FEENICS
Status last verified
Nov 2018
First submitted
16 Apr 2008
Last updated
19 Dec 2018
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Fragmin/ Dalteparin Sodium in people with Diabetic Foot Ulcer, run by Pfizer at 63 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 63 sites in United Kingdom, Sweden, Denmark, Russia, Poland and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jan 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing (time frame: Week 24 [end of treatment (EOT)] or early termination). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in